Cardiotoxicity profile of trastuzumab

Drug Safety

Volumn 31, Issue 6, 2008, Pages 459-467

  Ewer, Steven M ^a   Ewer, Michael S ^b,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Breast cancer; Congestive heart failure, drug induced; Monoclonal antibodies, general; Trastuzumab, adverse reactions; Trastuzumab, general

Indexed keywords

ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; DRUG EFFECT; FOLLOW UP; HEART DEATH; HEART EJECTION FRACTION; HEART FUNCTION; HISTOPATHOLOGY; HUMAN; INCIDENCE; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYMPTOM; TREATMENT OUTCOME; ULTRASTRUCTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; HEART DISEASES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 43849094005     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831060-00002     Document Type: Review

References (29)

1. Nahta R, Esteva F. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006; 8: 215
2. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84
3. Slamon DJ, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2-positive early breast cancer patients: BCIRG 006 study [abstract]. Breast Cancer Res Treat 2005; 94: S5
4. Joensuu H, Kellokumpu-Lehtinen P, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-20
5. Piccart-Gebhart MJ, Proctor M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72
6. Slamon D, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344 (11): 783-92
7. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-21
8. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B31. J Clin Oncol 2005; 23: 7811-9
9. Rastogi P, Jeong J, Geyer CE, et al. Five-year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/ cyclophosphamide → paclitaxel compared to AC → T with trastuzumab: LBA 513 [abstract]. In: ASCO 43rd Annual Meeting; 2007 Jun 1-5; Chigaco (IL). J Clin Oncol 2007; 25 (18S Part I): 6s
10. Suter TM, Proctor M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the Herceptin Adjuvant trial. J Clin Oncol 2007; 25: 3859-65
11. Slamon D, Eierman W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophophamide followed by docetaxel (ACT) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients [abstract]. 29th Annual San Antonio Breast Cancer Symposium; 2006 Dec 14-17; San Antonio (TX)
12. Billingham M. Role of endomyocardial biopsy in diagnosis and treatment of heart disease. In: Silver M, editor. Cardiovascular pathology. New York: Churchill Livingstone, 1991: 1465-8
13. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23: 7820-7
14. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008; 26: 1231-8
15. Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol 2008; 26: 1201-3
16. Ewer M, Lippman S. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005; 23 (13): 2900-2
17. Telli ML, Hunt MA, Carlson RW, et al. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007; 25: 3525-33
18. Ewer MS, Tan-Chiu E. Reversibility of trastuzumab cardiotoxicity: is the concept alive and well [letter]? J Clin Oncol 2007; 25: 5532-3
19. Gille L, Nohl H. Analysis of the molecular mechanism of adriamycin-induced cardiotoxicity. Free Radic Biol Med 1997; 23: 775-82
20. Herman EH, Zhang J, Hasinoff BB, et al. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines. Cancer Chemother Pharmacol 1997; 40: 400-8
21. Zhao YY, Baliga RR, Opel DJ, et al. Neuregulins promote survival and growth of cardiac myocytes: persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 1998; 273: 10261-9
22. Clerk A, Michael A, Sugden P. Stimulation of the p38 mitogen-activated protein kinase pathway in neonatal rat ventricular myocytes by the G protein-coupled receptor agonists, endothelin-1 and phenylephrine: a role in cardiac myocyte hypertrophy? J Cell Biol 1998; 142 (2): 523-35
23. Suter T, Cook-Bruns N, Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 2004 Jun; 13 (3): 173-83
24. Crone S, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Med 2002; 8: 459-65
25. 111Indium- trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 2007; 20: 46-51
26. Bryant J, Picot J, Baxter L, et al. Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review. Eur J Cancer 2007; 43: 1959-66
27. Aggarwal S, Pettersen MD, Bhambhani K, et al. B-Type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. Ped Blood Cancer 2007; 49: 812-6
28. Ewer MS, Perez EA, Baselga J, et al. Cardiac safety guidelines for the adjuvant use of trastuzumab (Herceptin) in HER2-positive early breast cancer [poster no. 176]. St Gallen Primary Therapy of Early Breast Cancer 10th International Conference; 2007 Mar 14-17; St Gallen, Switzerland
29. Ewer M, Yeh ET. Cancer and the heart. Hamilton, Ontario: Decker, 2006